


LISTING OF CLAIMS

This listing of claims will replace all prior versions of claims in the application.

1. (Previously presented) A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent optionally substituted, fused benzene;

R_C is -CH₂-R_L;

R_L is optionally substituted phenyl; and

R_N is hydrogen.


2-3. (Cancelled)

4. (Previously presented) A method according to claim 1, wherein the fused benzene is unsubstituted.

5. to 9. (Cancelled).

10. (Currently amended) A method according to claim 1, wherein R_L is substituted by one or more substituents selected from the group consisting of: C₁₋₇ alkyl; C₅₋₂₀ aryl; C₃₋₂₀ heterocyclyl; halo; hydroxy; ether; nitro; cyano; carbonyl groups; amino; sulfonamido; acylamido acylamino; ureido; acyloxy; thiol; thioether; sulfoxide; and sulfone.

11. (Currently amended) A method according to claim 10, wherein R_L is substituted by an ~~acylamido~~, wherein the acylamido is a ureido group, or an ~~amino~~, wherein the amino is a sulfonamido group.
12. (Original) A method according to claim 1, wherein the disease mediated by PARP is cancer, and there is additionally administered to the subject chemotherapy or radiation therapy.
13. (Previously presented) A method of potentiating tumour cells for treatment with ionising radiation or chemotherapeutic agents comprising administering to said cells a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:


A and B together represent optionally substituted, fused benzene;

R_C is $-\text{CH}_2-\text{R}_L$;

R_L is optionally substituted phenyl; and

R_N is hydrogen.

14. (Currently amended) A compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent optionally monosubstituted, fused benzene;

R_C is -CH₂-R_L;

R_L is substituted phenyl, wherein the substituents are selected from the group consisting of: C₆-

~~aryl~~; C₃₋₂₀ heterocyclyl; ester; amido; acyloxy; sulfonamido; ~~cyano~~; ureido; ~~acylamido~~;

~~thioether~~, thiol, SO₂R wherein R is C₁₋₇ alkyl, C₃₋₂₀ heterocyclyl or C₅₋₂₀ aryl, and sulfoxide, and

optionally further substituted; and

R_N is hydrogen.


15-16. (Cancelled)

17. (Previously presented) A compound according to claim 14, wherein the fused benzene is unsubstituted.

18. (Cancelled)

19. (Currently amended) A compound according to claim 14, wherein R_L is substituted by ~~an acylamide, wherein the acylamide is a ureido group, or a sulfonamido group.~~

20. (Previously presented) A pharmaceutical composition comprising a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent an optionally substituted, fused benzene;

R_C is -CH₂-R_L;

R_L is optionally substituted phenyl; and

R_N is hydrogen;

and a pharmaceutically acceptable carrier or diluent.



21-22. (Cancelled)

23. (Previously presented) The pharmaceutical composition of claim 20, wherein the fused benzene is unsubstituted.

24. (Currently amended) The pharmaceutical composition of claim 20, wherein R_L is substituted by one or more substituents selected from the group consisting of: C₁₋₇ alkyl; C₅₋₂₀ aryl; C₃₋₂₀ heterocyclyl; halo; hydroxy; ether; nitro; cyano; carbonyl groups; amino; sulfonamido; acylamido acylamino; ureido; acyloxy; thiol; thioether; sulfoxide; and sulfone.



25. (Currently amended) The pharmaceutical composition of claim 24, wherein R_L is substituted by an ~~acylamido~~, wherein the ~~acylamido~~ is a ureido group, or an ~~amino~~, wherein the ~~amino~~ is a sulfonamido group.

26. (Currently amended) A method of treatment of a disease of a human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of the formula:




or an isomer, salt, solvate, chemically protected form and prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

27. (Currently amended) A method of potentiating tumour cells for treatment with ionising radiation or chemotherapeutic agents comprising administering to said cells a compound of formula:




or an isomer, salt, solvate, chemically protected form, and prodrug thereof.

28. (Currently amended) A compound of the formula:



BEST AVAILABLE COPY



or an isomer, salt, solvate, chemically protected form and prodrug thereof.